1. Home
  2. BCDA vs VRME Comparison

BCDA vs VRME Comparison

Compare BCDA & VRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • VRME
  • Stock Information
  • Founded
  • BCDA N/A
  • VRME 1999
  • Country
  • BCDA United States
  • VRME United States
  • Employees
  • BCDA N/A
  • VRME N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • VRME EDP Services
  • Sector
  • BCDA Health Care
  • VRME Technology
  • Exchange
  • BCDA Nasdaq
  • VRME Nasdaq
  • Market Cap
  • BCDA 7.9M
  • VRME 6.9M
  • IPO Year
  • BCDA N/A
  • VRME N/A
  • Fundamental
  • Price
  • BCDA $2.18
  • VRME $3.60
  • Analyst Decision
  • BCDA Strong Buy
  • VRME Buy
  • Analyst Count
  • BCDA 1
  • VRME 1
  • Target Price
  • BCDA $25.00
  • VRME $1.50
  • AVG Volume (30 Days)
  • BCDA 52.4K
  • VRME 18.6M
  • Earning Date
  • BCDA 11-13-2024
  • VRME 11-12-2024
  • Dividend Yield
  • BCDA N/A
  • VRME N/A
  • EPS Growth
  • BCDA N/A
  • VRME N/A
  • EPS
  • BCDA N/A
  • VRME N/A
  • Revenue
  • BCDA $71,000.00
  • VRME $25,259,000.00
  • Revenue This Year
  • BCDA N/A
  • VRME N/A
  • Revenue Next Year
  • BCDA N/A
  • VRME $5.00
  • P/E Ratio
  • BCDA N/A
  • VRME N/A
  • Revenue Growth
  • BCDA N/A
  • VRME N/A
  • 52 Week Low
  • BCDA $1.63
  • VRME $0.58
  • 52 Week High
  • BCDA $8.85
  • VRME $5.00
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 49.10
  • VRME 66.27
  • Support Level
  • BCDA $2.05
  • VRME $1.45
  • Resistance Level
  • BCDA $2.36
  • VRME $5.00
  • Average True Range (ATR)
  • BCDA 0.21
  • VRME 0.96
  • MACD
  • BCDA -0.00
  • VRME 0.29
  • Stochastic Oscillator
  • BCDA 46.43
  • VRME 67.45

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About VRME VerifyMe Inc.

VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.

Share on Social Networks: